April 27 Apr 27
2015
03:15 PM - 4:15 PM
Monday Mon

Public-Private Partnerships for State-of-the-Art Countermeassures

Preparing for and limiting the effects of biological weapons could not only prevent casualties but reduces the incentives for an attack. Availability of countermeasures is also critical for an effective response to a pandemic/infectious disease disaster. This session will promote the importance of partnerships between the government, academia and industry in the development of new technologies through the case study and discussion of Vaxart. Dr. Latour will discuss what it is like to run a company which makes products for the US Government and will share ideas on how Public-Private Partnerships can be structured for maximal effectiveness. Dr. Latour will also discuss Vaxart’s recent experience of developing an Ebola vaccine in a tablet form. 

Vaxart is developing oral recombinant vaccines based on its proprietary oral vaccine platform. With modular creation using standard recombinant techniques, Vaxart can create new vaccines very quickly to protect against emerging pathogens such as avian influenza or biodefense threats.

Location

Li Ka Shing Learning & Knowledge Center (LKSC)
291 Campus Dr.
Palo Alto, CA 94305
USA

Loading Map...

Li Ka Shing Learning & Knowledge Center (LKSC)

291 Campus Dr.
Palo Alto CA, 94305
Get Directions

Speaker

Wouter Latour, MD, MBA, Chief Executive Officer and Director of Vaxart

Wouter Latour, MD, MBA: Chief Executive Officer and Director of Vaxart 

Vaxart is a privately owned company developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. With modular creation using standard recombinant techniques, Vaxart can create new vaccines very quickly to protect against emerging pathogens such as avian influenza or biodefense threats.

Dr. Latour brings more than 20 years of industry experience to Vaxart, including roles as vice president and director, Global Strategy and Business Development at SmithKline Beecham Biologicals (now GSK Vaccines) and as a strategic advisor for Novartis Pharma, Novavax and Berna Biotech (now J&J/Crucell). Most recently, Dr. Latour served as CEO and director at Trinity Biosystems, Inc., a company focusing on oral delivery of biopharmaceuticals. Dr. Latour earned his MD from the University of Amsterdam and his MBA from Stanford University.